Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pozelimab

A human immunoglobulin G4 (IgG4) monoclonal antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, pozelimab targets and binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). C5, a complement pathway protein, is expressed at high levels by the liver.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	WHO 10945
Code name:	REGN 3918 REGN-3918 REGN3918

pozelimab

Search NCI's Drug Dictionary